Mineralys Therapeutics, Inc.
MLYS
$25.64
-$0.45-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.66M | 20.98M | 13.88M | 9.68M | 8.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 246.04M | 45.34M | 38.28M | 41.13M | 46.75M |
| Operating Income | -246.04M | -45.34M | -38.28M | -41.13M | -46.75M |
| Income Before Tax | -241.07M | -39.34M | -32.23M | -36.93M | -43.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -241.07M | -39.34M | -32.23M | -36.93M | -43.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -241.07M | -39.34M | -32.23M | -36.93M | -43.27M |
| EBIT | -246.04M | -45.34M | -38.28M | -41.13M | -46.75M |
| EBITDA | -246.04M | -45.33M | -38.27M | -41.12M | -46.73M |
| EPS Basic | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 |
| Normalized Basic EPS | -1.78 | -0.30 | -0.25 | -0.33 | -0.41 |
| EPS Diluted | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 |
| Normalized Diluted EPS | -1.78 | -0.30 | -0.25 | -0.33 | -0.41 |
| Average Basic Shares Outstanding | 84.73M | 82.83M | 80.55M | 70.59M | 65.45M |
| Average Diluted Shares Outstanding | 84.73M | 82.83M | 80.55M | 70.59M | 65.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |